[PDF] Top 20 Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

... 12-month treatment period, of either ranibizumab ...of ranibizumab T&E and laser versus ranibizumab ...the treatment-free period was increased by one more ...If visual ... See full document

... to diabetic patients without retinal diseases or with other types of diabetic retinopathy ...for diabetic patients without retinal disease at 1 and 3 years after diagnosis, while inpatient costs ... See full document

... age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population ...2006, ranibizumab, a ... See full document

... the treatment pathway is difficult to capture in a Markov model given its memoryless properties (patients newly entering the blindness state are indistinguishable from those who have been there for at least one ... See full document

... Early Treatment Diabetics Retinopathy Study (ETDRS) fields) was determined automatically and analyzed by OCT software, by generating images using the Macular Cube 512 × 128 scan over 6 × 6 mm area, the cube ... See full document

... From January 1, 2004 to December 31, 2005, there were 367 CVI for patients from Cambridgeshire, Cambridge city, and Huntingdonshire. Two forms were incomplete (the type of VI was not stated). Of the 365 completed forms ... See full document

... best-corrected visual acuity, fundus photography, fluorescein angiography, and retinal thickness on ...fast macular thickness map protocol and software version ... See full document

... of macular edema was 4 months, and the mean baseline visual acuity was 57 letters ...score visual acuity improvement were ...from treatment with ... See full document

... ziv- aflibercept so that the small volume would minimize acute elevations in intraocular ...of aflibercept (2 ...of aflibercept have not been reported in eyes with ...mg aflibercept in the ... See full document

... severe visual impairment avoided per patients) due to longer time spent in the model by the ...severe visual impairment avoided per ...provider perspective and compared with no ... See full document

... of treatment-naïve AMD patients who received induction therapies with intravitreal injections of aflibercept or ranibizumab to estimate the population that may require intensive treatment, and ... See full document

... retina. Visual impairment occurs when edema affects the central retina or macula (diabetic macular edema, or ...DME). Macular edema is reversible in the early ... See full document

... between visual acuity and health-related quality of life in DME using data from four IAI studies 22 (NCT01512966 and ...part, due to the volume of data available and the wide range of visual ...AMD ... See full document

... laser treatment technique is required to individualize the ...from edema , location of collaterals, and presence of retinal traction influence the exact mode of therapy within the above general ... See full document

... other treatment for macular edema within the previous 10 ...the treatment has not yet been approved in ...the macular map analysis protocol of the RS-3000 SD-OCT was ...Early ... See full document

... and aflibercept) every 2 weeks resulted in markedly improved trough binding activity, so the short-term use of biweekly dosing may be an attractive treatment option for those eyes that respond within 2 ... See full document

... either Ranibizumab or Aflibercept between ...therefore treatment-naïve nvAMD in at least one ...corrected visual acuity (BCVA) and optical coherence tomography (OCT) was performed For ... See full document

... anti-VEGF treatment with the macular disease type has been examined using the Pearson ’ s chi-square ...pharmacological treatment/ therapeutic modality and best corrected visual acuity (BCVA) ... See full document

... The NEI VFQ-25 is comprised of: one general health item (VF1) and 24 items (VF2 to VF25) that assess visual func- tioning and the impact of vision problems on physical and social functioning and emotional ... See full document

... of aflibercept for the treatment of DME and results from Protocol T, many ophthalmolo- gists are switching patients from ranibizumab or beva- cizumab to aflibercept, especially those with ... See full document